AI may be the next big thing in the tech industry, but you might not realize the important role it has also started to play in healthcare. The human lifespan has been gradually growing over time, but it may be poised for a huge jump soon, thanks to AI innovations. The technology’s ability to harness previously unimaginable amounts of data and analyze it with ever more sophisticated algorithms is creating research breakthroughs at a phenomenal pace. Many experts believe that the result could be the ability to add decades, and eventually even centuries, to human life. If you want to get in on the ground floor of this longevity revolution, there are currently three main companies to consider.
The Central Players
Eli Lilly has become a household name thanks to its groundbreaking treatments for everything from Alzheimer’s to diabetes. In the past few years, the company has partnered with several AI-focused drug research companies including Atomwise, Verge Genomics, and XtalPi. Its commitment to heavy use of AI combined with its long-standing reputation for innovation could make Eli Lilly a major player in lifespan enhancement over the coming years.
Johnson & Johnson took a bit of a hit during the COVID-19 pandemic due to issues with its vaccine. But the company has a long legacy in the healthcare industry, and it has smartly positioned itself for the AI revolution. In partnership with Winterlight Labs, the company is using AI speech analysis for early detection of Alzheimer’s disease. It’s also using AI throughout its medical device division, with a focus on more personalized tools. This puts the company in an excellent position for the longevity revolution.
Sanofi has long focused on three core components of the pharmaceutical field: vaccines, chronic illnesses, and rare diseases. The company is all-in on AI, with the goal of using it to power nearly of its operations. If this initiative takes off as expected, Sanofi could emerge as a breakout lifespan improvement company.
Lisa Fritscher has no positions in the companies mentioned. Stocks.News has positions in Johnson and Johnson.
Did you find this insightful?
Bad
Just Okay
Amazing
Disclaimer: Information provided is for informational purposes only, not investment advice. We do not recommend buying or selling stocks. Stock price discussions are based on publicly available data. Readers should conduct their own research or consult a financial advisor before investing. Owners of this site have current positions in stocks mentioned thru out the site, Please Read Full Disclaimer for details Here https://app.stocks.news/page/disclaimer
Contributing Writer
Lisa Fritscher has been a contributing writer for App.Stock.News since 2024. Lisa has been interested in investing since winning The Stock Market Game in high school. In more than a decade as a professional writer, she has written consumer-facing financial information and advice articles for a wide variety of publications. She has a Bachelor of Arts in Psychology from the University of South Flori...